ANUH PHARMA
|
ANUH PHARMA Last 5 Year Financial Ratios History
[Standalone]
| Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.22 | 6.10 | 5.67 | 5.71 | 9.33 |
| CEPS(Rs) | 9.16 | 8.49 | 8.68 | 4.26 | 4.99 |
| DPS(Rs) | 2.00 | 1.75 | 1.50 | 2.75 | 2.75 |
| Book NAV/Share(Rs) | 48.14 | 42.66 | 38.04 | 64.74 | 65.69 |
| Tax Rate(%) | 23.78 | 21.88 | 26.24 | 25.32 | 27.89 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.78 | 9.67 | 10.25 | 7.31 | 9.30 |
| EBIT Margin(%) | 9.10 | 8.29 | 9.22 | 6.42 | 10.24 |
| Pre Tax Margin(%) | 8.96 | 7.97 | 8.75 | 6.03 | 10.06 |
| PAT Margin (%) | 6.83 | 6.22 | 6.46 | 4.50 | 7.25 |
| Cash Profit Margin (%) | 8.66 | 8.66 | 9.88 | 6.71 | 7.77 |
| Performance Ratios | |||||
| ROA(%) | 9.63 | 8.99 | 8.63 | 5.06 | 10.44 |
| ROE(%) | 15.90 | 15.11 | 16.12 | 8.75 | 14.87 |
| ROCE(%) | 21.05 | 19.33 | 19.75 | 10.87 | 20.56 |
| Asset Turnover(x) | 1.41 | 1.44 | 1.34 | 1.12 | 1.44 |
| Sales/Fixed Asset(x) | 5.31 | 4.97 | 4.55 | 5.20 | 13.71 |
| Working Capital/Sales(x) | 3.62 | 3.84 | 4.48 | 5.28 | 4.16 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.19 | 0.20 | 0.22 | 0.19 | 0.07 |
| Receivable days | 105.71 | 90.17 | 77.87 | 89.32 | 82.39 |
| Inventory Days | 52.54 | 59.98 | 59.23 | 59.91 | 42.34 |
| Payable days | 125.45 | 117.42 | 125.15 | 130.55 | 83.81 |
| Valuation Parameters | |||||
| PER(x) | 11.03 | 14.09 | 15.91 | 10.21 | 7.25 |
| PCE(x) | 8.70 | 10.13 | 10.40 | 13.69 | 13.54 |
| Price/Book(x) | 1.65 | 2.01 | 2.37 | 1.80 | 2.06 |
| Yield(%) | 2.51 | 2.04 | 1.66 | 2.36 | 2.03 |
| EV/Net Sales(x) | 0.74 | 0.86 | 1.03 | 1.09 | 1.03 |
| EV/Core EBITDA(x) | 6.77 | 7.94 | 8.01 | 12.17 | 9.57 |
| EV/EBIT(x) | 8.14 | 10.27 | 10.99 | 16.37 | 10.05 |
| EV/CE(x) | 0.97 | 1.20 | 1.34 | 1.02 | 1.39 |
| M Cap / Sales | 0.76 | 0.89 | 1.05 | 0.95 | 1.06 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 8.39 | 12.66 | 40.72 | -4.27 | 34.68 |
| Core EBITDA Growth(%) | 9.98 | -5.38 | 102.79 | -20.82 | 34.87 |
| EBIT Growth(%) | 18.46 | 0.30 | 98.80 | -38.14 | 38.26 |
| PAT Growth(%) | 18.38 | 7.47 | 98.78 | -38.78 | 41.51 |
| EPS Growth(%) | 18.38 | 7.47 | -0.61 | -38.78 | 41.51 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | 0.01 | 0.07 | 0.27 | 0.03 |
| Current Ratio(x) | 1.91 | 1.98 | 1.70 | 1.37 | 2.03 |
| Quick Ratio(x) | 1.46 | 1.37 | 1.12 | 0.99 | 1.46 |
| Interest Cover(x) | 64.61 | 25.76 | 19.99 | 16.23 | 55.16 |
| Total Debt/Mcap(x) | - | 0.01 | 0.03 | 0.15 | 0.01 |
Compare Financial Ratios of peers of ANUH PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ANUH PHARMA | ₹1,141.8 Cr | -3.8% | -7.5% | 153.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹361,400.0 Cr | -1.5% | -5.8% | 55.3% | Stock Analytics | |
| CIPLA | ₹108,147.0 Cr | -5.9% | -8.4% | 45.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹100,664.0 Cr | -4.3% | -0.1% | 15.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,917.8 Cr | -3.7% | -1.8% | 84.3% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,703.0 Cr | -6.1% | -4.1% | 19.8% | Stock Analytics | |
ANUH PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ANUH PHARMA | -3.8% |
-7.5% |
153.2% |
| SENSEX | -1.6% |
-2.1% |
19% |
You may also like the below Video Courses
